Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
296 stopped studies mapped to Breast Adenocarcinoma and descendants · 97% state a reason
Over the 296 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | NBE-Therapeutics AG | End of Program | Other (stated, no rule matched) |
| NCT04720664 | Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer(OASIS) | Phase 2 | terminated | Jan 22, 2021 | Georgetown University | Lack of efficacy | Efficacy / futility |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating… | Phase 1 | terminated | Dec 4, 2019 | Jonsson Comprehensive Cancer Center | enrollment | Enrollment / accrual |
| NCT01712815 | PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer | N/A | terminated | Oct 24, 2012 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous… | Phase 1 / Phase 2 | terminated | Nov 20, 2020 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | Genmab | Sponsor decision | Sponsor / business decision |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
| NCT05809895 | Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With…(AdvanTIG-211) | Phase 2 | withdrawn | Apr 12, 2023 | Novartis Pharmaceuticals | Business decision, not driven by safety concerns; no new safety signals have been observed in the… | Safety / toxicity |
| NCT05255666 | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer… | Phase 2 | withdrawn | Feb 24, 2022 | Washington University School of Medicine | No drug | Other (stated, no rule matched) |
| NCT02067741 | CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer | Phase 2 | terminated | Feb 20, 2014 | Swiss Cancer Institute | The SAKK board decided to prematurely end the life-long follow-up of the trial SAKK 21/12, as 90%… | Other (stated, no rule matched) |
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT04305236 | Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast… | Phase 2 | terminated | Mar 12, 2020 | University of California, Irvine | Halted due to study funding | Funding |
| NCT05774886 | Implantable Microdevice for TNBC - Pilot Study | Phase 1 | withdrawn | Mar 20, 2023 | Dana-Farber Cancer Institute | On hold | Other (stated, no rule matched) |
| NCT04335006 | A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus… | Phase 3 | terminated | Apr 6, 2020 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian… | Early Phase 1 | withdrawn | May 10, 2022 | OHSU Knight Cancer Institute | PI discretion | Other (stated, no rule matched) |
| NCT03002103 | A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel… | Phase 3 | suspended | Dec 23, 2016 | SynCore Biotechnology Co., Ltd. | study design reconsideration | Other (stated, no rule matched) |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects… | Phase 1 | suspended | Dec 2, 2020 | Bellicum Pharmaceuticals | Due to a Dose Limiting Toxicity in another sister trial with same technology. | Safety / toxicity |
| NCT04489940 | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative… | Phase 2 | terminated | Jul 28, 2020 | EMD Serono Research & Development Institute, Inc. | The study was prematurely discontinued by the sponsor due to probability of success which was too… | Enrollment / accrual |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT03137693 | Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer | N/A | terminated | May 3, 2017 | H. Lee Moffitt Cancer Center and Research Institute | no responders/lack of efficacy | Efficacy / futility |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid… | Phase 1 | terminated | Jul 15, 2016 | Calithera Biosciences, Inc | Insufficient efficacy of drug; no safety concern | Safety / toxicity |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT02658812 | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be… | Phase 2 | terminated | Jan 20, 2016 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT03666819 | Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone… | Phase 2 | withdrawn | Sep 12, 2018 | Mayo Clinic | Manufacturer will not be supporting this study | Drug supply |
| NCT04249167 | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple… | Early Phase 1 | withdrawn | Jan 30, 2020 | Mayo Clinic | study was dropped | Other (stated, no rule matched) |
| NCT04291950 | Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women | — | withdrawn | Mar 2, 2020 | University of Arizona | Principal investigator is moving to a new institution. Study is closing. | Investigator |
| NCT05233696 | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive… | Phase 2 | withdrawn | Feb 10, 2022 | University of Colorado, Denver | Low Accrual | Enrollment / accrual |
| NCT04268693 | Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer(EDC-TNBC) | — | withdrawn | Feb 13, 2020 | George Washington University | Study never initiated due to COVID pandemic, staffing changes | COVID-19 / pandemic |
| NCT05093387 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative… | Phase 1 | withdrawn | Oct 26, 2021 | Northwestern University | funding issues and pharmacy preparation for the drug | Funding |
| NCT02124902 | Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and… | Phase 2 | terminated | Apr 28, 2014 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT02474173 | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | Phase 1 | terminated | Jun 17, 2015 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT03579472 | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast… | Phase 1 | terminated | Jul 6, 2018 | M.D. Anderson Cancer Center | Due to the fact that the sponsor decided not to move forward with the development of M7824 | Sponsor / business decision |
| NCT04876378 | Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone… | — | terminated | May 6, 2021 | University of California, San Francisco | Funding | Funding |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT03750240 | Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy | N/A | terminated | Nov 21, 2018 | NYU Langone Health | technical difficulties for scans on the research MRI system | Other (stated, no rule matched) |
| NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive… | Phase 1 / Phase 2 | terminated | May 29, 2015 | Vanderbilt-Ingram Cancer Center | Interim analysis - toxicity | Safety / toxicity |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies… | Phase 1 / Phase 2 | terminated | Oct 25, 2021 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT04349111 | An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" | N/A | withdrawn | Apr 16, 2020 | Xoft, Inc. | Lack of site participation | Other (stated, no rule matched) |
| NCT03674242 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the… | Phase 2 / Phase 3 | terminated | Sep 17, 2018 | ERYtech Pharma | sponsor decision | Sponsor / business decision |
| NCT05227131 | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer(MARGARET) | Phase 2 | withdrawn | Feb 7, 2022 | MedSIR | Funder decided to not continue the study | Other (stated, no rule matched) |
| NCT04512261 | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With…(TOPAZ) | Phase 1 / Phase 2 | withdrawn | Aug 13, 2020 | Reva Basho | Study withdrawn due to change in treatment landscape for HER2+ metastatic breast cancer. | Other (stated, no rule matched) |
| NCT05244434 | Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With… | N/A | withdrawn | Feb 17, 2022 | City of Hope Medical Center | PI withdrawn | Other (stated, no rule matched) |
| NCT02720185 | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With… | Phase 2 | terminated | Mar 25, 2016 | University of Wisconsin, Madison | Study terminated early due to COVID-19 related slow enrollment and funding | COVID-19 / pandemic |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT04351230 | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast… | Phase 2 | withdrawn | Apr 17, 2020 | Academic and Community Cancer Research United | There are no patients enrolled on this study and all efforts are being discontinued | Enrollment / accrual |
| NCT01234532 | Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed…(0927GCC) | Phase 2 | terminated | Nov 4, 2010 | University of Maryland, Baltimore | low accrual | Enrollment / accrual |
| NCT03630809 | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 | Phase 2 | terminated | Aug 15, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Quality of the data originating from prior versions of the protocol has been affected by protocol… | COVID-19 / pandemic |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 21, 2023source: clinicaltrials